Search
forLearn
5 / 801 resultslearn ACETYL TETRAPEPTIDE-2
learn copper tripeptide-1
learn PTT-6®
learn thiamin
Research
5 / 309 resultsresearch Effects of Yiqi Huayu Chinese Medicine on the Expression of MMP-2/TIMP-2 in BPH Rats
Yiqi Huayu medicine can effectively reduce BPH in rats by lowering MMP-2 levels and blood vessel growth.
research Expression of matrix metalloproteinases and tissue inhibitor of matrix metalloproteinases in the hair cycle
MMP-2 and MMP-9 help hair grow, while their inhibitors peak when hair growth slows.
research Honokiol protects skin cells against inflammation, collagenolysis, apoptosis, and senescence caused by cigarette smoke damage
Honokiol helps protect skin from damage and aging caused by cigarette smoke.
research Human Scalp Dermal Papilla and Fibrous Sheath Cells have a different expression profile of Matrix Metalloproteinases in vitro when compared to Scalp Dermal Fibroblasts
Scalp dermal papilla and fibrous sheath cells have different MMP expression than scalp dermal fibroblasts.
research Efeitos da doxazosina e da combinação doxasina mais finasterida sobre a interação parenquina-estroma na prostata de rato
The combined treatment of Finasteride and Doxazosin affects prostate tissue by reducing cell growth and altering hormone levels.
Community Join
5 / 1000+ resultscommunity when is kintor going to start phase 3 for gt20029?
The conversation is about the timeline for Kintor's phase 3 trials for GT20029 and the potential release of the product in three years. It also mentions treatments like Minoxidil, finasteride, and RU58841.
community Phase II for Technoderma Therepeutic's TDM-105795 set to begin in April tentatively
Phase II for TDM-105795 for Androgenic Alopecia is set to begin in April 2023. The study aims to evaluate the efficacy and safety of TDM-105795 in male subjects.
community Trial for TDM-105795 update from research office
The trial for TDM-105795 has been completed, and it was in phase 2A. The discussion seeks input on the next phases, 2B or 3, based on safety and efficacy.
community Kintor Pharma Announces Positive Top-line U.S. Phase I Trial Results of GT20029, the World’s First Topical Use PROTAC Compound
The conversation discusses positive initial trial results for GT20029, a topical compound for hair loss that degrades androgen receptors, potentially requiring only weekly application. Participants express hope for this treatment to be more effective and convenient than current options like Minoxidil, Finasteride, and RU58841.
community TDM-105795 phase 2 results are in!
TDM-105795 showed promising hair growth results, with higher efficacy than placebo and minimal side effects. It activates dormant hair follicle stem cells and may maintain gains without immediate loss, unlike minoxidil.